Active substance
Results for the substance certolizumab pegol
1 result
About this active substance
Certolizumab pegol is a biologic medication used to treat chronic inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and Crohn's disease. It is a pegylated monoclonal antibody that works by inhibiting tumor necrosis factor-alpha (TNF-α), a protein involved in inflammatory processes. By reducing TNF-α activity, certolizumab pegol helps alleviate inflammation, pain, and joint damage.
The mechanism of action of certolizumab pegol involves specifically binding to TNF-α, preventing its interaction with cell surface receptors. This reduces inflammation and the abnormal immune response associated with autoimmune diseases. Due to pegylation (attachment of a polyethylene glycol chain), the medication has a longer duration of action and improved distribution in the body.
Certolizumab pegol is administered as a subcutaneous injection, typically once every two or four weeks, depending on the treatment regimen and the condition being treated. The initial dose may include multiple injections to quickly achieve therapeutic levels. Treatment is long-term and requires regular monitoring to assess efficacy and safety.
While effective, certolizumab pegol may cause side effects. The most common include injection site reactions (redness, pain, swelling), upper respiratory tract infections, headache, and nausea. In rare cases, severe infections (such as tuberculosis), allergic reactions, or autoimmune disorders may occur. It is contraindicated in patients with active severe infections or hypersensitivity to the active substance. Before starting treatment, patients should be tested for tuberculosis and other latent infections.
The mechanism of action of certolizumab pegol involves specifically binding to TNF-α, preventing its interaction with cell surface receptors. This reduces inflammation and the abnormal immune response associated with autoimmune diseases. Due to pegylation (attachment of a polyethylene glycol chain), the medication has a longer duration of action and improved distribution in the body.
Certolizumab pegol is administered as a subcutaneous injection, typically once every two or four weeks, depending on the treatment regimen and the condition being treated. The initial dose may include multiple injections to quickly achieve therapeutic levels. Treatment is long-term and requires regular monitoring to assess efficacy and safety.
While effective, certolizumab pegol may cause side effects. The most common include injection site reactions (redness, pain, swelling), upper respiratory tract infections, headache, and nausea. In rare cases, severe infections (such as tuberculosis), allergic reactions, or autoimmune disorders may occur. It is contraindicated in patients with active severe infections or hypersensitivity to the active substance. Before starting treatment, patients should be tested for tuberculosis and other latent infections.